Figure 5.

Enhanced levels of Akt activation in human prostate cancers lacking PTEN expression. Whole-cell lysates were prepared from the human prostate cancer cell lines LNCaP, DU145, PC3, and prostate cancer xenografts LAPC-4 and LAPC-9, which were passaged as subcutaneous tumors in male severe combined immunodeficient mice, and from normal human prostate tissue from three individual patients. The levels of phosphorylated (Top) and total (Bottom) Akt were measured by using antibodies as described in Fig. 1. The status of the PTEN gene in each tumor is designated + (wild type) or − (mutant) as determined (1, 2, 4).